Login to Your Account

2nd Phase III CellCept Failure Sends Aspreva Shares Down

By Trista Morrison

Thursday, June 28, 2007
Shares of Aspreva Pharmaceuticals Corp. sank to a new 52-week low on Wednesday after the company disclosed that the induction portion of a Phase III clinical trial of CellCept (oral mycophenolate mofetil) in lupus nephritis missed its primary endpoint. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription